~~<i id='7FB7CD2679'><strike id='7FB7CD2679'><tt id='7FB7CD2679'><pre id='7FB7CD2679'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：entertainment 2025-09-06 03:53:54 - browse：58195

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： A public scorecard can help hold safety

knowledge

leisure time

entertainment

leisure time

focus

AdobeBigbusinessespoisedtoprofitfromtheadvanceofartificialintelligenceinhealthcarearepushingbackagai

WSS

Sanders adds drug shortage policies to pandemic preparedness bill

Group opposing PBM reform sets lobbying record

In early work, researchers turn to CRISPR to treat Alzheimer's

Startup Neumora takes a novel depression drug to Phase 3

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

In early work, researchers turn to CRISPR to treat Alzheimer's

focus

comprehensive

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Why hospitals are withdrawing from US News rankings

Continuity nursing helped my family in our darkest PICU moments

Medicare to cover more brain scans for Alzheimer’s patients

Heart attack and stroke risk calculators need revising

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

In Memoriam: Notable people who died in 2023

Why doctors need education on FDA device approval process

Alkermes shareholders re

eGenesis tests gene

leisure time

Medicare Advantage today, explained in one chart

Custom gene therapy hints at new path for rare disease treatments

Biden tests positive for Covid

Custom gene therapy hints at new path for rare disease treatments

At Orexo, a ‘turning point’ for everything but digital health

Medicare to cover more brain scans for Alzheimer’s patients

entertainment

leisure time

focus

focus